Literature DB >> 29925575

Implementation of Duchenne Muscular Dystrophy Care Considerations.

Jennifer G Andrews1, Kristin Conway2, Christina Westfield3, Christina Trout4, F John Meaney5, Katherine Mathews4, Emma Ciafaloni6, Christopher Cunniff7, Deborah J Fox8, Dennis Matthews9, Shree Pandya6.   

Abstract

BACKGROUND: Duchenne muscular dystrophy (DMD) is an X-linked disorder characterized by progressive muscle weakness and multisystem involvement. Recent advances in management of individuals with DMD have prolonged survival. Lack of standardized care spurred an international collaboration to develop consensus-based care considerations for diagnosis and management. In this study, we evaluate adherence to considerations at selected sites.
METHODS: We collaborated with the Muscular Dystrophy Surveillance, Tracking, and Research Network. Our sample included males with DMD and Becker muscular dystrophy <21 years as of December 31, 2010, with 1 health care encounter on or after January 1, 2012. We collected data from medical records on encounters occurring January 1, 2012, through December 31, 2014. Adherence was determined when frequency of visits or assessments were at or above recommendations for selected care considerations.
RESULTS: Our analytic sample included 299 individuals, 7% of whom (20/299) were classified as childhood-onset Becker muscular dystrophy. Adherence for neuromuscular and respiratory clinician visits was 65% for the cohort; neuromuscular assessments and corticosteroid side effect monitoring measures ranged from 16% to 68%. Adherence was 83% for forced vital capacity and ≤58% for other respiratory diagnostics. Cardiologist assessments and echocardiograms were found for at least 84%. Transition planning for education or health care was documented for 31% of eligible males.
CONCLUSIONS: Medical records data were used to identify areas in which practice aligns with the care considerations. However, there remains inconsistency across domains and insufficiency in critical areas. More research is needed to explain this variability and identify reliable methods to measure outcomes.
Copyright © 2018 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2018        PMID: 29925575     DOI: 10.1542/peds.2017-4006

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  Characterizing Expiratory Respiratory Muscle Degeneration in Duchenne Muscular Dystrophy Using MRI.

Authors:  Alison M Barnard; Donovan J Lott; Abhinandan Batra; William T Triplett; Rebecca J Willcocks; Sean C Forbes; William D Rooney; Michael J Daniels; Barbara K Smith; Krista Vandenborne; Glenn A Walter
Journal:  Chest       Date:  2021-09-15       Impact factor: 10.262

2.  Current care practices for patients with Duchenne muscular dystrophy in China.

Authors:  Shu Zhang; Shaoxia Wang; Yuru Dong; Xinyu Chen; Miao Hu; Sen Kou; Chunyan Zhang; Shiwen Wu; Yaping Tian
Journal:  Brain Dev       Date:  2022-06-09       Impact factor: 2.272

3.  Evaluating Implementation of the Updated Care Considerations for Duchenne Muscular Dystrophy.

Authors:  Katherine S Ong; Kathi Kinnett; Rieza Soelaeman; Lauren Webb; Jennifer S Bain; Ann S Martin; Christina Westfield; Julie Bolen; Natalie Street
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

4.  Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state.

Authors:  Kristin M Conway; Scott D Grosse; Lijing Ouyang; Natalie Street; Paul A Romitti
Journal:  Muscle Nerve       Date:  2022-02-09       Impact factor: 3.852

5.  Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Authors:  G Solé; E Salort-Campana; Y Pereon; T Stojkovic; K Wahbi; P Cintas; D Adams; P Laforet; V Tiffreau; I Desguerre; L I Pisella; A Molon; S Attarian
Journal:  Rev Neurol (Paris)       Date:  2020-04-20       Impact factor: 2.607

6.  Clinical Management of Duchenne Muscular Dystrophy in the Netherlands: Barriers to and Proposals for the Implementation of the International Clinical Practice Guidelines.

Authors:  Lotte Heutinck; Maaike van Gameren; Jan J G M Verschuuren; Alexander C H Geurts; Merel Jansen; Imelda J M de Groot
Journal:  J Neuromuscul Dis       Date:  2021

7.  Compliance to DMD Care Considerations in the Netherlands.

Authors:  Lotte Heutinck; Saskia L S Houwen-van Opstal; Yvonne D Krom; Erik H Niks; Jan J G M Verschuuren; Merel Jansen; Imelda J M de Groot
Journal:  J Neuromuscul Dis       Date:  2021
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.